Sanofi executives are upbeat about the potential advantages of its monoclonal antibody-based approach to the prevention of RSV infections in infants, the future growth of the company’s Dupixent franchise, and the progress of its novel anticancers.
Sanofi CEO Paul Hudson has highlighted the potential competitive advantage of its Phase III monoclonal antibody nirsevimab over other approaches being evaluated for the prophylaxis of RSV infection in infants.
Nirsevimab “has the potential to be a truly transformational medicine for young children,” Hudson told analysts during the company’s 28...
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
